TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06094140
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure.
Study: NCT06094140
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85mg/m2 intravenously on day 1
Study: NCT06094140
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150mg/m2 intravenously on day 1
Study: NCT06094140
Drug: Pegylated G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6mg by subcutaneous injection to be given on day 3 of each cycle.
Study: NCT05654649
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
Study: NCT05654649
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
Study: NCT06383884
Drug: Patritumab Deruxtecan
Normalized name: patritumab deruxtecan
DrugBank: Patritumab (DB12090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patritumab deruxtecan will be administered as an IV infusion Q3W on Day 1 of each 21-day cycle as a fixed dose regimen of 5.6 mg/kg Q3W.
Study: NCT05469490
Drug: navoximod
Normalized name: Navoximod
DrugBank: Navoximod (DB15439)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A small molecule inhibitor with potent inhibition of IDO1 enzymatic activity as shown both in vitro and in vivo. As the main function of IDO1 is the regulation of acquired immune tolerance, and its expression in tumor- and dendritic cells in tumor draining lymph nodes negatively correlates with cancer prognosis and survival, navoximod-mediated IDO1 inhibition may restore immune reactivity towards tumors.
Study: NCT05469490
Drug: NLG802 (indoximod Prodrug)
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An anti-tumor immunomodulator with the active ingredient of 1-methyl-D-tryptophan (NSC- 721782, 1-MT), which is an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway that increases the bioavailability of indoximod by leveraging existing mechanisms of absorption, increasing the exposure of indoximod.
Study: NCT04793100
Drug: Treatment standardization with aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For patients requiring intravitreal injection
Study: NCT01714089
Drug: Interferon beta 1a
Normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05096715
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Infusion
Study: NCT05096715
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous Infusion
Study: NCT05550337
Drug: Trifarotene 0.005 % Topical Cream
Normalized name: trifarotene 0.005 % Topical Cream
DrugBank: Trifarotene (DB12808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream
Study: NCT04091243
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Experimental drug for the treatment of glucocorticoid induced osteoporosis
Study: NCT04762186
Drug: human SARS-CoV 2 specific T lymphocytes
Normalized name: SARS-COV
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In dose level one, SARS-CoV-2 infected patients will receive 1,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In dose level two SARS-CoV-2 infected patients will receive 5,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In parallel, all patients will receive the current SoC treatment for COVID-19.
Study: NCT05719961
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part I: A single dose of 0.2U/kg is administered.
Study: NCT05719961
Drug: Insulin Aspart 30 Injection
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part II: A single dosewas administered
Study: NCT05604417
Drug: TAZEMETOSTAT
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage and treatment timings per protocol
Study: NCT05604417
Drug: Zandelisib
Normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage and treatment timings per protocol
Study: NCT06613776
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 capsules of amoxicillin 500mg, 2 grams in total, one hour before surgery
Study: NCT06697522
Drug: Atropine Sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low concentration atropine (0.01%)
Study: NCT05137860
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
Study: NCT06711679
Drug: Low-dose ropivacaine
Normalized name: ethinyl estradiol
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 ml/Kg ropivacaine
Study: NCT06711679
Drug: Medium-dose of ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1ml/Kg ropivacaine
Study: NCT06711679
Drug: High-dose ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 ml/Kg ropivacaine
Study: NCT06466421
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine 60 mg orally once daily for 3 months
Study: NCT06466421
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg after each dialysis session (thrice weekly). Dose may be titrated after 2 weeks, according to response and tolerability, to 100 mg orally once daily for 3 months.
Study: NCT04680910
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted propofol infusion in TRD patients will induce sedation with maximal expression of EEG slow waves and minimal burst suppression.
Study: NCT05805098
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting on day 1, venetoclax will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2 and 400 mg on day 3. The patient then continues to take the 400mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day.
Study: NCT05805098
Drug: Homoharringtonine
Normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On day 1, homoharringtonine 1 mg/m2 IV will be given, and will continue for 5 days.
Study: NCT05805098
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On day 1, cytarabine 100 mg/m2 IV will be given, and will continue for 5 days.
Study: NCT05881811
Drug: HSK16149，probenecid, cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4
Study: NCT05474664
Drug: Camostat mesylate
Normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. 4\~12 years old: Camostate mesylate 100 mg, 2 times a day~2. greater than 13 years old: Camostate mesylate 100 mg, 3 times a day
Study: NCT05924893
Drug: Naltrexone Hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naltrexone film
Study: NCT05290116
Drug: HAIC Combined with Tislelizumab and Apatinib
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Tislelizumab and Apatinib treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Tislelizumab 200 mg, ivdrip, Q3W; Apatinib 250 mg, po, QD.
Study: NCT05924893
Drug: Carboxy methyl cellulose
Normalized name: Methyl cellulose
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxy methyl cellulose drops
Study: NCT04800627
Drug: Pevonedistat
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06166108
Drug: transversus abdominis plane (TAP) block in Abdominal hysterectomy
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparative evaluation of magnesium sulphate versus dexamethasone as an adjuvant to bupivacaine in ultrasound guided transversus abdominis plane block for Abdominal hysterectomy as postoperative analgesia.
Study: NCT04487925
Drug: A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CFA will be administered in combination with Follitropin beta.
Study: NCT04487925
Drug: Up to three modified natural cycles with Follitropin beta.
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin beta in a low dose will be given.
Study: NCT04880213
Drug: M5049
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.
Study: NCT04880213
Drug: M5049
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.
Study: NCT04677504
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
Study: NCT04677504
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.
Study: NCT04677504
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered intravenously at a dose of 25 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
Study: NCT04677504
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered intravenously at a dose of 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
Study: NCT04880213
Drug: M5049
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.
Study: NCT06488170
Drug: Tildrakizumab
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world clinical practice.
Study: NCT05254249
Drug: Lactobacillus Plantarum IS-10506
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU
Study: NCT05288543
Drug: IPG7236- Multiple ascending dose
Normalized name: IODINE 1 kg in 1 kg TOPICAL LIQUID [ASCEND]
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state
Study: NCT05528848
Drug: Carfentanil, C-11
Normalized name: Carfentanil, C-11
DrugBank: Carfentanil, C-11 (DB15360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational radiotracer to be injected by IV as s a bolus during both study PET/CT scans.
Study: NCT05528848
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-selective opioid antagonist injected by IV parenterally during the second study PET/CT scan only.
Study: NCT05528848
Drug: Loperamide Hydrochloride
Normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loperamide is an FDA- approved, over-the-counter drug for the control and symptomatic relief of acute or chronic diarrhea given orally prior to the optional HC third PET/CT scan only.
Study: NCT06121570
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study: NCT06121570
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Study: NCT06121570
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
Study: NCT06107920
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diverting stoma- neoadjuvant chemotherapy - colectomy - +/- adjuvant chemotherapy
Study: NCT01775098
Drug: allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No arms will not be change as the study as been closed.
Study: NCT05474846
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06351904
Drug: RAG-01
Normalized name: RAG-17
DrugBank: RAG-17 (DB18503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAG-01 is a therapeutic small activating RNA (saRNA).
Study: NCT04903002
Drug: 24-IU oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will self-administer a 2-week course of 24-IU intranasal oxytocin \[4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
Study: NCT04903002
Drug: 48-IU oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will self-administer a 2-week course of 48-IU intranasal oxytocin \[4-IU per puff (24-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
Study: NCT04607252
Drug: Metformin plus Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral
Study: NCT04607252
Drug: Megestrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: megestrol acetate 160mg per day, oral
Study: NCT06408246
Drug: Guanfacine
Normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.
Study: NCT06408246
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.
Study: NCT06517199
Drug: Olanzapine 2.5 MG
Normalized name: olanzapine 2.5 MG
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: olanzapine 2.5 mg/day for 28 days
Study: NCT06517199
Drug: Olanzapine 5 MG
Normalized name: olanzapine 5 MG
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: olanzapine 5 mg/day for 28 days
Study: NCT05571813
Drug: CKD-341
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 1tablets under fasting condition
Study: NCT05490043
Drug: ATG-101
Normalized name: ATG-101
DrugBank: ATG-101 (DB17162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-101 will be administered intravenously once every 28 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
Study: NCT06061484
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard weight-based dosing per Ehtiopian national guidelines
Study: NCT06284473
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine is an N-methyl-D aspartate receptor agonist
Study: NCT05060471
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
Study: NCT04739423
Drug: clenbuterol (CST-103), nadolol (CST-107), matching placebo
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clenbuterol (CST-103) and matching placebo orange capsules; nadolol (CST-107) and matching placebo white capsules
Study: NCT00000730
Drug: Trimetrexate glucuronate
Normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000730
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000730
Drug: Pentamidine isethionate
Normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000730
Drug: Sulfamethoxazole-Trimethoprim
Normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05117034
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
Study: NCT04724226
Drug: Camrelizumab; Apatinib
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoablation~Drug: Camrelizumab and Apatinib Camrelizumab (200mg), iv, Q3W; Apatinib (250mg), po, QD
Study: NCT05773989
Drug: CYP2C19 genotype guided P2Y12 monotherapy
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
Study: NCT05773989
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
Study: NCT05052554
Drug: QR-504a
Normalized name: mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal (IVT) injection
Study: NCT03702036
Drug: molibresib
Normalized name: Molibresib
DrugBank: Molibresib (DB16239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
Study: NCT05181215
Drug: Monomethyl Fumarate 190 Mg
Normalized name: Monomethyl fumarate
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x oral 95 mg capsules, delayed-release
Study: NCT05826574
Drug: Brensocatib
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets.
Study: NCT05826574
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules.
Study: NCT05826574
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules.
Study: NCT05181215
Drug: Diroximel Fumarate 462 mg
Normalized name: Diroximel fumarate
DrugBank: Diroximel fumarate (DB14783)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 x 231 mg capsules, delayed-release
Study: NCT00002123
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002123
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05008341
Drug: Solriamfetol 150 mg Oral Tablet
Normalized name: Solriamfetol 150 MG Oral Tablet
DrugBank: Solriamfetol (DB14754)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-dose 150 mg tablet orally administered.
Study: NCT00002179
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no